Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (VSTM), a biopharmaceutical company focused on developing treatments for RAS/MAPK pathway-driven cancers, has announced its management team's participation in three upcoming investor conferences in May 2025:
- H.C. Wainwright BioConnect Conference: Fireside chat on May 20 at 12:00 PM ET
- RBC Capital Markets Healthcare Conference: Fireside chat on May 20 at 3:35 PM ET
- A.G.P. Healthcare Company Showcase: Virtual fireside chat on May 21 at 10:20 AM ET
Live webcasts will be available on Verastem's website with replays archived for approximately 90 days.
Verastem Oncology (VSTM) has secured a $75 million private placement through a combination of common stock and pre-funded warrants. The company is offering shares at $7.00 per share for approximately $24 million, and $51 million in pre-funded warrants at $6.9999 per warrant with a $0.0001 exercise price.
The placement was led by RTW Investments, with participation from BVF Partners, Nantahala Capital, Octagon Capital, OrbiMed, and Stonepine Capital Management. The closing is expected around April 28, 2025.
The proceeds will fund:
- Potential launch of avutometinib and defactinib in recurrent low-grade serous ovarian cancer
- Continued clinical development of products including VS-7375
- Working capital and general corporate purposes
Verastem Oncology (VSTM) has received FDA clearance for its Investigational New Drug (IND) application of VS-7375, an oral KRAS G12D inhibitor. The company plans to initiate a Phase 1/2a trial in mid-2025 for advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers.
Initial data from partner GenFleet Therapeutics' Phase 1/2 study showed promising results with oral bioavailability and no dose-limiting toxicities across six dose levels, achieving partial responses in pancreatic and advanced lung cancer patients. The upcoming trial's starting dose will be based on GenFleet's efficacy findings to accelerate progress.
GenFleet will present preliminary dose escalation results at the 2025 ASCO Annual Meeting in Chicago (May 30-June 3). The abstract (#3013) is embargoed until May 22, 2025.
Verastem Oncology (VSTM) has announced new equity compensation grants to fifteen employees. The company granted stock options to purchase 164,500 shares of common stock to fourteen new employees at an exercise price of $5.82 per share, matching the closing price on April 1, 2025. Additionally, one new employee received 83,333 restricted stock units.
The grants were made under Nasdaq's inducement grant exception (Rule 5635(c)(4)). The stock options and 50,000 RSUs will vest 25% after one year, with remaining shares vesting quarterly over three years. The additional 33,333 RSUs will vest based on sales milestone achievements. All vestings are contingent on continued employment with Verastem Oncology.
Verastem Oncology (VSTM) announced multiple presentations at the upcoming AACR Annual Meeting 2025, showcasing significant developments in their cancer treatment pipeline. VS-7375, their oral KRAS G12D inhibitor, demonstrated superior potency compared to other KRAS G12D inhibitors in preclinical models. When combined with cetuximab, it achieved complete responses in colorectal cancer models.
The company reported that their FAK inhibitor, when combined with avutometinib, enhanced tumor regression in LGSOC xenograft models by inhibiting MAPK, PI3K, and YAP/TEAD signaling pathways. Additionally, the combination of avutometinib (RAF/MEK clamp) with a pan-RAF inhibitor showed strong tumor regressions in NRAS- and BRAF-driven tumor models.
Verastem Oncology (VSTM) reported its Q4 and full-year 2024 financial results, highlighting significant pipeline progress. The FDA granted priority review for avutometinib plus defactinib combination in KRAS mutant recurrent LGSOC, with a PDUFA date of June 30, 2025.
The company ended Q4 2024 with $88.8 million in cash and investments, with pro forma cash of $151.3 million including debt refinancing and equity issuance. Q4 operating expenses were $31.6 million, with a net loss of $64.6 million ($1.33 per share).
Key developments include filing an IND for VS-7375 (KRAS G12D inhibitor), progress in the RAMP 205 pancreatic cancer trial, and strategic agreements with Oberland Capital and IQVIA to support commercialization efforts. The company expects its cash runway to extend through potential product launch into Q4 2025.
Verastem Oncology (VSTM) announced multiple presentations at the upcoming Society of Gynecologic Oncology 2025 Annual Meeting. The key highlight is an oral presentation of additional analyses from the Phase 2 RAMP 201 trial, which evaluates avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC). This data served as the basis for their NDA currently under FDA Priority Review.
The presentations include subgroup analyses by KRAS mutational status, an investigator-sponsored study of the same drug combination in gynecologic mesonephric cancer, and a preclinical poster on treatment resistance. The company will also maintain an exhibition booth (#622) at the conference, which takes place March 14-17 in Seattle.
Verastem Oncology (VSTM), focusing on RAS/MAPK pathway-driven cancer treatments, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 1:00 PM EST.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Verastem's website. The recorded session will remain available for approximately 90 days following the presentation on the company's website at www.verastem.com.
Verastem Oncology announced key 2025 priorities and milestones for its RAS/MAPK pathway-driven cancer pipeline. The FDA granted priority review for avutometinib plus defactinib combination therapy for recurrent KRAS mutant LGSOC, with a PDUFA date of June 30, 2025. The company plans a U.S. commercial launch in mid-2025.
Key developments include: ongoing RAMP 205 trial in metastatic pancreatic cancer with updated data expected in Q1 2025; VS-7375 IND filing planned for Q1 2025 with Phase 1/2a study initiation in mid-2025; and recent financing providing runway beyond potential FDA approval.
The company's 2025 strategic priorities focus on: launching avutometinib plus defactinib in the U.S. for LGSOC; expanding the combination therapy to other solid tumors; and advancing its early-stage pipeline, including VS-7375, a KRAS G12D inhibitor.